Skip to main content
Scroll To Top
Home
Contact Us
Login
Create account
Search form
Search
About Us
Vision, Mission and Values
What We Do
Become a Member
Services
Board of Directors
Staff
Contact Us
Build Skills & Knowledge
Calendar of Events
PNY Core
Racial Equity
Leadership Development
Recorded Programs
Resources
Regional Calendar
Network
Networks & Working Groups
Committees & Advisory Groups
Member Directory
Public Policy
Why We Engage
Policy Priorities & Positions
Committee
News
Member News
Insights
Editorial Guidelines
Appointments and Transitions
PNY News
Jobs in Philanthropy
About Us
Vision, Mission and Values
What We Do
Become a Member
Membership Eligibility and Structure
Services
Conference Facilities
Consultant & Vendor Recommendations
Family Philanthropy Resources
Fiscal Sponsorship
Salary & Benefits Survey
Member Directory
Board of Directors
Committees & Advisory Groups
Past Board Chairs
Staff
Contact Us
Build Skills & Knowledge
Calendar of Events
PNY Core
Legal Series
Philanthropy 101
ESS
Financial Series
Evaluation Series
Policy Series
Racial Equity
Leadership Development
Recorded Programs
Resources
Regional Calendar
Network
Networks & Working Groups
Committees & Advisory Groups
Member Directory
Public Policy
Why We Engage
Policy Priorities & Positions
Committee
News
Member News
Insights
Editorial Guidelines
Appointments and Transitions
PNY News
Jobs in Philanthropy
Home
Contact Us
Login
Create account
You are here
Home
»
News
»
FDA Promised a ‘Lower-Cost Option’ to EpiPen, but the Price Isn’t Any Lower
FDA Promised a ‘Lower-Cost Option’ to EpiPen, but the Price Isn’t Any Lower
Wednesday, November 28, 2018
Read more @ STAT
Find More By
News type
Sector News
Funding Area
Health
